The sector had a decent day, although participation was not great. We seem to be on the verge of breaking higher (at least in the XBI) but it will be difficult to do unless the rally is broader in its scope. Of course, one cannot complain too much given that we are generally moving higher […]
June 4 Biotech Update
Despite the lack of any real thesis changing news, ASCO seemed to be fairly typical. There will be a couple of big winners but more losers as you have both bad data and data that was good but not good enough for inflated expectations. Given the dearth of major data, I wonder if there will […]
Dave-Trading – June 2018
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
May 17 Biotech Update
Some interesting moves and data coming out of the ASCO abstracts. There are some questions answered with these abstracts, although more questions remain unanswered. I suspect that many of the morning moves in these stocks will be moderated by the end of the day as ultimately there is nothing thesis changing that can come out […]
May 2 Biotech Update
It does not seem like today is going to be a good day for the sector but we have to see how it all plays out. There is some important earnings that might have import for the broader sector. 1. GILD had an absolute awful quarter. The only positive was that the CART crushed expectations […]
April 18 Biotech Update
We certainly seem to be moving away from the macro concerns to more sector specific issues, which is good to finally see. Of course, we are only one news cycle away from the macro driving the sector again but for now it seems like the sector survived and seems to be doing well. 1. BPMC […]
April 16 Biotech Update
We had the Syrian strikes over the weekend and for all intents and purposes it was typically political theater, which makes it enough for all sides to declare victory and move on. Perhaps there will be further consequences in the future but for now it is unlikely to be a significant macro worry for the […]
April 4 Biotech Update
The market is a volatility machine. We went so long without any real volatility and now all we have a whiplash moves. In periods of these, the goal is to trade less (at least for those with a longer term view). Let the valuations come to you and do not worry about the swings. It […]
March 15 Biotech Update
We might be seeing a little of the broadening rally that I talked about as the XBI seems to be modestly underperforming the IBB the past couple days. The move in the sector was mainly concentrated in the XBI (more heavily weighted towards the SMID) versus the IBB (more heavily weighted towards the large caps) […]
March 8 Biotech Update
Some interesting news happening in the sector that might have some pin action more broadly. In general, it seems like the broader market is getting its legs, which is likely good for the sector as it has been doing well without additional M&A (which is very likely coming this year). 1. There was a healthcare […]
February 22 Biotech Update
A little pick up in the news flow but clearly the sector has been tied to the broader market in the immediate term. The spike in interest rates caused by the Fed minutes took the market and the sector down. While the direct impact of raising interest rates on the sector is minimal, it does […]
February 21 Biotech Update
There is not a lot of news to start the day, so this can be relatively quick. In general, it seems that the market is slowly getting back to a lower volatility period, which is not necessarily bad. The sector was doing well when volatility was lower, so expectations should be that would continue in […]
January 5 Biotech Update
JPM is just about here and traders are suddenly turning anxious. The days leading up to the meeting have gone without a big splash deal and doubts are starting to creep into investors about the potential that JPM falls flat without a major catalyst. There is still plenty of time but that is a real […]
December 12 Biotech Update
The sector sort of held in there for the ASH hangover but was sort of hit or miss. With ASH winding down, we are seeing the winners selling shares and the losers trying to cut losses. At this point, it is either a wait for JPM or hope for some news out of nowhere. 1. […]
December 11 Biotech Update
There is no ASH hangover quite yet but it usually comes pretty quick after the conference. Perhaps this year will be different given that outside of a few good days, there was no real run up into the conference. There is a lot to talk about and so I will take the next couple days […]
November 1 Biotech Update
The sector is doing well with the release of the ASH abstracts. There is not a ton to glean from the data but there are certainly some nice updates that we should follow to see what happens when we get the full presentations at ASH. In some ways, the more important driver of the sector […]
August 31 Biotech Update
The good news and move for the sector continues. In isolation the move higher seems a stretch in terms of the fundamental news that we have seen the past week. The news has been good but we have had weeks with better news and did not have this reaction. Clearly sentiment has changed in the […]
August 23 Biotech Update
The sector had a good day yesterday with an early retracement this morning. I am a little surprised that there is not more weakness in the broader market. Last night Trump threatened a shutdown over the border wall funding, which is one of the risks I have been talking about. Does the market think that […]
August 22 Biotech Update
Another day with not a lot of news but we at least have some news to talk about in the doldrums of summer. 1. While we were expect the BPMC data at ESMO, they PRed the data early and to be honest it is not that exciting. In patients with FGFR4 activited the ORR was […]
August 18 Biotech Update
The whole market is looking heavy and the IWM broke below key support. The sector is not going to be able to hold up if this continues but luckily there is still the rising 200 day just below $300 on the IBB that could be additional support. So would the IBB breaking below $300 surprise […]
